This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2019 Feb 2;393(10170):402.

doi: 10.1016/S0140-6736(18)32763-6.

Baricitinib for systemic lupus erythematosus

Kai Yuan¹, Guangrui Huang¹, Xiaopu Sang¹, Anlong Xu²

Affiliations

Affiliations

¹ School of Life Sciences, Beijing University of Chinese Medicine, Beijing 100029, China.
² School of Life Sciences, Beijing University of Chinese Medicine, Beijing 100029, China. Electronic address: xuanlong@bucm.edu.cn.

PMID: 30712894
DOI: 10.1016/S0140-6736(18)32763-6

Comment

Baricitinib for systemic lupus erythematosus

Kai Yuan et al. Lancet. 2019.

. 2019 Feb 2;393(10170):402.

doi: 10.1016/S0140-6736(18)32763-6.

Authors

Kai Yuan¹, Guangrui Huang¹, Xiaopu Sang¹, Anlong Xu²

Affiliations

¹ School of Life Sciences, Beijing University of Chinese Medicine, Beijing 100029, China.
² School of Life Sciences, Beijing University of Chinese Medicine, Beijing 100029, China. Electronic address: xuanlong@bucm.edu.cn.

PMID: 30712894
DOI: 10.1016/S0140-6736(18)32763-6

No abstract available

PubMed Disclaimer

Comment in

Baricitinib for systemic lupus erythematosus - Authors' reply.
Wallace DJ, Furie RA, Tanaka Y, de Bono S, Hoffman RW. Wallace DJ, et al. Lancet. 2019 Feb 2;393(10170):402-403. doi: 10.1016/S0140-6736(18)32749-1. Lancet. 2019. PMID: 30712893 No abstract available.

Comment on

Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial.
Wallace DJ, Furie RA, Tanaka Y, Kalunian KC, Mosca M, Petri MA, Dörner T, Cardiel MH, Bruce IN, Gomez E, Carmack T, DeLozier AM, Janes JM, Linnik MD, de Bono S, Silk ME, Hoffman RW. Wallace DJ, et al. Lancet. 2018 Jul 21;392(10143):222-231. doi: 10.1016/S0140-6736(18)31363-1. Lancet. 2018. PMID: 30043749 Clinical Trial.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Medical
- MedlinePlus Health Information